As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Probably the most famous of them was Baby Faye in 1984, who lived for 21 days with a baboon’s heart. They didn’t work because ...

A leading Dundee academic clinician has been awarded an honorary professorship by Ukraine’s oldest medical school for his ...

That is a pretty explosive statement that strikes at the heart of a major talking point among Manchester United supporters. The status of Peter Schmeichel and Edwin van der Sar as legendary United ...

I lead with my heart and what I feel is best for them ... postured to respond rapidly to crises across the United States European, African, and Central Command theaters. Stationed across ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...